Abstract: Described herein is a bi-functional compound for removing macrophage migration inhibitory factor (MIF) or immunoglobulin G (IgG). Further described herein is a pharmaceutical composition which comprise these bi-functional compounds. Further described herein is a method for treating disease states and/or conditions with the compounds or the composition. The disease states and/or conditions are mediated through MIF/IgG or where MIF/IgG is a contributing factor to the development and perpetuation of diseases and/or conditions, such as autoimmune diseases and cancer, among others.
Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.
Type:
Grant
Filed:
June 7, 2023
Date of Patent:
September 10, 2024
Assignee:
YALE UNIVERSITY
Inventors:
David Spiegel, Ryan Murelli, Andrew Zhang
Abstract: The present disclosure relates, in part, to enhanced weathering systems and/or apparatuses and methods of use thereof. In one aspect, the present disclosure provides a method of at least partially sequestering CO2 from an influent aqueous solution comprising aqueous and/or gaseous CO2. In another aspect, the present disclosure provides a method of at least partially sequestering CO2 from a gaseous CO2 source. In another aspect, the present disclosure provides systems and/or apparatuses suitable for use in the methods described herein. In another aspect, the present disclosure provides a method of optimizing the design and operation of a system for at least partial sequestration of CO2 from a water source.
Type:
Grant
Filed:
April 10, 2023
Date of Patent:
September 10, 2024
Assignee:
YALE UNIVERSITY
Inventors:
Joachim Katchinoff, Noah Planavsky, Jacob Jordan, Dean Takahashi, Sinead Crotty, Justin Freiberg
Abstract: The invention provides a system for normothermic, ex vivo restoration and preservation of an intact mammalian brain, and other organs. In certain aspects, the system is capable of preserving a brain as well as other organs, maintaining cellular integrity and cellular function for hours post mortem or after global ischemia. The invention also provides synthetic brain perfusate formulations, including a novel brain perfusion medium (BPM), which are able to reduce reperfusion injury, stimulate recovery from hypoxia, prevent edema and metabolically support the energy needs of brain function.
Type:
Application
Filed:
April 29, 2024
Publication date:
September 5, 2024
Applicant:
Yale University
Inventors:
Stefano Daniele, Nenad Sestan, John Silbereis, Zvonimir Vrselja
Abstract: Disclosed herein are compositions and methods useful for the diagnosis, assessment, and characterization of endometriosis in a subject in need thereof, based upon the expression level of at least one miRNA that is associated with endometriosis.
Abstract: This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a mammal undergoing such chemotherapy.
Abstract: Described herein are methods and compositions useful to reduce (partially/inhibit or completely—prevent) skin cancer development in an individual in need thereof.
Abstract: Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.
Abstract: Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.
Abstract: A system for estimating attenuation coefficients from only single photon emission computed tomography (SPECT) emission data using deep neural networks includes an artificial neural network based upon machine learning system estimating attenuation maps for SPECT emission data, and associated attenuation correction method.
Type:
Grant
Filed:
April 17, 2020
Date of Patent:
August 27, 2024
Assignee:
YALE UNIVERSITY
Inventors:
Luyao Shi, Chi Liu, John Onofrey, Hui Liu
Abstract: The present invention provides novel transition-metal precatalysts that are useful in preparing active coupling catalysts. In certain embodiments, the precatalysts of the invention are air-stable and moisture-stable. The present invention further provides methods of making and using the precatalysts of the invention.
Type:
Grant
Filed:
February 27, 2023
Date of Patent:
August 27, 2024
Assignee:
YALE UNIVERSITY
Inventors:
Nilay Hazari, Patrick Melvin, Damian Hruszkewycz
Abstract: The present invention provides compositions and methods of preparing airway cells. In one aspect, an epithelial airway cell derived from an induced pluripotent stem (iPS) cell characterized by expression of airway cell surface markers and an ability to proliferate is described. In another aspect, methods of differentiating an iPS into an epithelial airway cell is provided. Engineered lungs, methods of making such engineered lungs comprising the epithelial airway cells and treating respiratory disorders are also disclosed.
Abstract: In various aspects and embodiments the invention provides compositions and methods for facilitating cell penetration of a cargo molecule. In another aspect, the invention provides a method of preventing viral infection in a subject in need thereof, the method comprising providing to the subject a therapeutically effective amount of a polypeptide comprising a cell-penetrating peptide and a retromer binding site.
Type:
Grant
Filed:
May 24, 2019
Date of Patent:
August 13, 2024
Assignee:
YALE UNIVERSITY
Inventors:
Daniel DiMaio, Pengwei Zhang, Gabriel Monteiro Da Silva, Weiya Bai
Abstract: In one aspect, the present disclosure provides a microRNA-33 (miR-33) inhibitor comprising a peptide nucleic acid covalently bound to a pH low insertion peptide. In another aspect, the present disclosure provides a method of treating pulmonary fibrosis in a subject, the method comprising administering to the subject a therapeutically effective amount of the miR-33 inhibitor. In some embodiments, the pulmonary fibrosis is idiopathic pulmonary fibrosis.
Type:
Grant
Filed:
May 13, 2022
Date of Patent:
August 13, 2024
Assignees:
YALE UNIVERSITY, UNIVERSITY OF CONNECTICUT
Inventors:
Farida Ahangari, Naftali Kaminski, Carlos Fernandez-Hernando, Raman Bahal
Abstract: Provided herein, in some embodiments, are devices, systems and methods for high-throughput single-cell polyomics (e.g., genomic, epigenomic, proteomic and/or phenotypic profile) analyses.
Abstract: The present invention relates to compounds which function as antibody mimetic compounds. These compounds are bifunctional/multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (PSMA) and a FC receptor binding moiety which modulates an FC immune receptor, preferably a Fc?RI receptor. Compounds according to the present invention bind selectively to cancer cells which upregulate PSMA and through that interaction, place the Fc receptor binding moiety of the compound in proximity to a Fc receptor, preferably a Fc?RI receptor, which can modulate (preferably, upregulate) a humoral response in a patient to cancer cells. Through this biological action of the compounds according to the present invention, cancer cells, including metastatic cancer cells, especially prostate cancer cells can be immune regulated, resulting in the favorable therapy of cancer in a patient.
Type:
Grant
Filed:
December 15, 2020
Date of Patent:
July 23, 2024
Assignee:
YALE UNIVERSITY
Inventors:
David A. Spiegel, Patrick McEnaney, Kelly Fitzgerald
Abstract: Techniques are described to construct an electromagnetic resonator by arranging a resonant structure within a super-conducting cavity. The architecture of the design may provide a low loss superconducting cavity resonator that may exhibit multiple modes. The multimode nature of this resonator is produced in part by the resonant structure in such a way that allows the modes of the resonator to be adjusted through adjustment of the resonant structure rather than by having to alter the physical dimensions of the cavity, as would otherwise be required in a conventional superconducting cavity resonator. In some embodiments, the resonant structure may include a suspended superconductor comprising metal and/or metallized parts.
Type:
Application
Filed:
February 17, 2022
Publication date:
July 11, 2024
Applicant:
Yale University
Inventors:
Chan U Lei, Suhas Ganjam, Lev Krayzman, Robert J. Schoelkopf lll, Luigi Frunzio
Abstract: Poly(amine-co-ester) polymers, methods of forming active agent-load polyplexes and particles therefrom, and methods of using them for delivery of nucleic acid agents with optimal uptake have been developed. Examples demonstrate critical molecular weights in combination with exposed carboxylic and/or hydroxyl groups, and methods of making. Typically, the compositions are less toxic, more efficient at drug delivery, or a combination thereof compared to a control other transfection reagents. In some embodiments, the compositions are suitable for in vivo delivery, and can be administered systemically to a subject to treat a disease or condition.
Abstract: The invention features a composition comprising a potent cytotoxic compound and a pH low insertion peptide, where, e.g., the cytotoxic compound cannot be used alone due to a lack of targeting. The pH low insertion peptide targets cytotoxic compounds to acidic diseased tissue, translocates cytotoxic compounds across plasma membranes into the cytosols of cells in acidic diseased tissues and induces cell death predominantly in the targeted acidic diseased tissue.
Type:
Grant
Filed:
January 28, 2020
Date of Patent:
July 9, 2024
Assignees:
Yale University, University of Rhode Island Board of Trustees
Inventors:
Yana K. Reshetnyak, Oleg A. Andreev, Anna Moshnikova, Donald M. Engelman